ABCL
|Abcellera Biologics Inc
NASDAQ
USD 2.04
+0.06|+3.03%
Current Price
USD 2.04
Change
+USD 0.06 (3.03%)
P/E Ratio
Dividend Yield
Market Cap
596.97M
Volume
2.49M
Open
USD 2.00
Previous Close
USD 1.98
52-Week High
USD 4.34
52-Week Low
USD 1.89
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Carl L.G. Hansen Ph.D.
Employees:596
Headquarters:Vancouver, Canada
Website:www.abcellera.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions